Editorial: Visual loss caused by corticosteroid-induced glaucoma: How to avoid it

Retina

Volumn 29, Issue 8, 2009, Pages 1057-1061

  Spaeth, George L ^a   Monteiro De Barros, Daniela S ^a   Fudemberg, Scott J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CORTICOSTEROID; DEXAMETHASONE SODIUM PHOSPHATE; FLUOCINOLONE ACETONIDE; FLUOROMETHOLONE; HYDROCORTISONE; HYDROCORTISONE ACETATE; LOTEPREDNOL ETABONATE; PILOCARPINE; PREDNISOLONE ACETATE; PROSTAGLANDIN DERIVATIVE; STEROID; TRIAMCINOLONE ACETONIDE;

APHAKIA; DRUG CONTRAINDICATION; DRUG TREATMENT FAILURE; EDITORIAL; EYE DISEASE; GLAUCOMA; GLAUCOMA SURGERY; HUMAN; INTRAOCULAR PRESSURE; OPTIC NERVE LESION; PSEUDOPHAKIA; QUALITY OF LIFE; RETINA DISEASE; SIDE EFFECT; TRABECULECTOMY; UVEITIS; VISUAL IMPAIRMENT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; VISUAL DISORDER;

ADRENAL CORTEX HORMONES; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; VISION, LOW;

EID: 70349115672     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181b32cfd     Document Type: Editorial

References (39)

1. McLean JM. Use of ACTH and cortisone. Trans Am Ophthalmol Soc 1950;48:293-296.
2. Francois J. Cortisone et tension oculaire. Ann Ocul 1954;187: 805-816.
3. Jones R, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006;17:163-167.
4. Roth SM, Spaeth GL, Starita RJ, Birbillis EM, Steinmann WC. The effects of postoperative corticosteroids on trabeculectomy and the clinical course of glaucoma: five-year follow-up study. Ophthalmic Surg 1991;22:724-729.
5. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61. (Pubitemid 36401766)
6. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcin-olone for refractory diabetic macular edema. Ophthalmology 2002;109:920-927.
7. Gillies MC, Sutter FKP, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2006;113:1533-1538.
8. Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for treatment of macular edema associated with central vein occlusion. Arch Ophthalmol 2004;122:1131-1136.
9. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005;112:1916-1921.
10. Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intra-vitreal triamcinolone acetonide for refractory chronic pseu-dophakic cystoid macular edema. J Cataract Refract Surg 2003;29:27-33.
11. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. Three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004;111:2044-2049.
12. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979;77:171-180.
13. Degenring RF, Jonas JB. Intravitreal injection of triamcino-lone acetonide as treatment of chronic uveitis. Br J Ophthalmol 2003;87:361.
14. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular oedema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 2001;119:1380-1383.
15. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oe-dema in uveitis. Clin Exp Ophthalmol 2001;29:2-6.
16. Jonas JB, Schlichtenbrede F. Visual acuity and pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases. Eye 2008;22:869-873.
17. Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol 1963;70:500-507.
18. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: II. The effect of dexamethasone on the glaucomatous eye. Arch Ophthalmol 1963;70:492-499.
19. Becker B, Hahn KA. Topical corticosteroids and heredity in primary open-angle glaucoma. Am J Ophthalmol 1964;54: 543-551.
20. Davies TG. Tonographic survey of the close relatives of patients with chronic simple glaucoma. Br J Ophthalmol 1968; 52:32-39.
21. Podos SM, Becker B, Morton WR. High myopia and primary open-angle glaucoma. Am J Ophthalmol 1966;62:1038-1043.
22. Know AK, Lam DS, Ng JS, Fan DS, Chew SJ, Tso MO. Ocular-hypertensive response to topical steroids in children. Ophthalmology 1997;104:2112-2116.
23. Lam DS, Fan DS, Ng JS, Yu CB, Wong CY, Cheung AY. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Experiment Ophthalmol 2005;33:252-258.
24. Ohji M, Kinoshita S, Ohmi E, Kuwayama Y. Marked intraocular pressure response to instillation of corticosteroids in children. Am J Ophthalmol 1991;112:450-454.
25. Spaeth GL. Traumatic hyphema, angle recession, dexametha-sone hypertension, and glaucoma. Arch Ophthalmol 1967;78: 714-721.
26. Gaston H, Absolon MJ, Thurtle OA, Sattar MA. Steroid responsiveness in connective tissue diseases. Br J Ophthalmol 1983;67:487-490.
27. Becker B. Diabetes mellitus and primary open-angle glaucoma. Am J Ophthalmol 1971;71:1-16.
28. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963;70:482-491.
29. Ticho U, Ben DD. Developmental glaucoma aggravated by topical steroids. Ann Ophthalmol 1971;3:1257-1259.
30. Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y, Chalam KV. Corticosteroids and glaucoma risk. Drugs Aging 1999; 15:439-450.
31. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin 1992;10:505-510.
32. Bernstein HN, Schwartz B. Effects of long term systemic steroids on ocular pressure and tonographic values. Arch Ophthalmol 1962;68:742.
33. Cantrill HL, Palmberg PF, Zink HA, Waltman SR, Podos SM, Becker B. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol 1975;79:1012-1017.
34. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye 2006;20:407-416.
35. Bayer A, Harasymowycz P, Henderer JP, Steinmann WG, Spaeth GL. Validity of a new disk grading scale for estimating glaucomatous damage: correlation with visual field damage. Am J Ophthalmol 2002;133:758-763.
36. Spaeth GL, Henderer J, Steinmann W. The Disc Damage Likelihood Scale (DDLS): its use in the diagnosis and management of glaucoma. Highlights Ophthalmol 2003;31:4-19.
37. Danesh-Meyer H, Ku JY, Papchenko TL, Jayasundera T, Hsiang JC, Gamble GD. Regional correlation of structure and function in glaucoma, using the Disc Damage Likelihood Scale, Heidelberg Retina Tomograph, and Visual Fields. Ophthalmology 2006;113:603-611.
38. Holekamp NM, Thomas MA, Pearson A. The safety profile of long-term, highdose intraocular corticosteroid delivery. Am J Ophthalmol 2005;139:421-428.
39. Rubin B, Taglienti A, Rothman RF, Marcus CH, Serle JB. The effect of selective laser trabeculoplasty on intraocular pressure in patients with intravitreal steroid-induced elevated intraocular pressure. J Glaucoma 2008;17:287-292.